British national newspaper The Times reported on Thursday that senior sources in the British government expect that a verdict on whether US pharmaceutical company Pfizer Inc's (NYSE:PFE) COVID-19 vaccine works, will be available before the results are in on British pharmaceutical company AstraZeneca Plc's (STO:AZN)(LON:AZN) competing vaccine.
The Times report said that Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas.
Reportedly, Pfizer's Chief Executive, Albert Bourla, had previously said the company could release data on whether or not the vaccine works as early as October 2020.
Pfizer had said this week if trials are successful the company expects to file for emergency authorisation of the vaccine candidate from US regulators shortly after it has enough safety data in late November 2020.
According to Reuters news agency, Britain has supply deals for six vaccine candidates, including frontrunners from Pfizer and AstraZeneca.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results